My watch list
my.chemeurope.com  

my.chemeurope.com

With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Vivecon



Vivecon™ is an investigational new drug in development for the treatment of HIV infection. It is a maturation inhibitor.

Mechanism of action

Vivecon targets the gag polyprotein precursor, the main structural protein responsible for assembly and budding of virion particles. By binding to the gag polyprotein, vivecon prevents its cleavage by the protease enzyme into functional subunits. Unlike the protease inhibitors, vivecon binds the gag protein, not the protease enzyme. The resulting virus particles are structurally defective and are incapable of spreading infection through the body.[1]

References

  1. ^ Myriad Genetics Submits IND on Vivecon 6 Dec 2007. CNNmoney.com
v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase Inbitors (NRTI)		Abacavir (ABC) • Didanosine • Emtricitabine° • Lamivudine (3TC)° • Stavudine • Zidovudine (AZT)° • Tenofovir° • Apricitabine† • Stampidine† • Elvucitabine† • Racivir† • Zalcitabine‡
Non-Nucleoside
Reverse Transcriptase Inhibitiors (NNRTI)		Efavirenz° • Nevirapine • Etravirine† • Rilpivirine† • Loviride‡ • Delavirdine‡
Protease Inhibitors (PI)Atazanavir • Darunavir • Fosamprenavir • Lopinavir° • Nelfinavir • Ritonavir • Saquinavir • Tipranavir • Amprenavir‡ • Indinavir‡
Entry/fusion inhibitorsEnfuvirtide • Maraviroc • Vicriviroc† • PRO 140†
Integrase inhibitorsRaltegravir • Elvitegravir†
Maturation inhibitorsBevirimat† • Vivecon™†
Combined formulationsCombivir • Atripla • Trizivir • Truvada • Kaletra • Epzicom
Other & experimental agentsFoscarnet • Synergistic enhancers • Epigallocatechin gallate • Portmanteau inhibitors • Globoidnan A • Griffithsin • Diarylpyrimidines • Calanolide A
†Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent. °Preferred first-line agent.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vivecon". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE